Parnax Lab Ltd vs Cipla Ltd

A side-by-side comparison of Parnax Lab Ltd (506128) and Cipla Ltd (CIPLA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Cipla Ltd leads 506128 vs CIPLA on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

13.80
P/E ratio
30.68
1.71
P/B ratio
3.42
0.00%
Dividend yield
0.89%
₹10.03
EPS
₹48.02

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

14.40%
Return on equity
11.60%
14.00%
Return on capital
15.00%
14.00%
EBITDA margin
21.00%
6.38%
Net margin
13.71%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

13.95%
Revenue CAGR (3Y)
7.37%
10.91%
Profit CAGR (3Y)
10.88%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹159 Cr
Market cap
₹1.19L Cr
₹188 Cr
Revenue
₹28,163 Cr
₹12 Cr
Net profit
₹3,862 Cr
0.87
Debt / equity
0.00
Parnax Lab Ltd
  • + ["Company is expected to give good quarter"]
  • ["Though the company is reporting repeated profits, it is not paying out dividend", "Company might be capitalizing the interest cost"]
Cipla Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.26%"]
Parnax Lab Ltd full analysis Cipla Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

Parnax Lab Ltd vs Cipla Ltd: Share Price, Valuation & Which to Buy | DocStoX